Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Retired pro football hall-of-famer Barry Sanders revealed he had a heart attack in 2024. But now he working to help other ...

In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained ...